IBIO
iBio, Inc.
$1.69
+1.20%
$84.0M
No data for this timeframe.
Vol
Market Cap$84.0M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders17 funds
Inst. Value$10.5M
Inst. Activity4 buys / 0 sells
Insider Activity3B / 0S
Insider Net $$95.6K
SEC Reports8
Press Releases1
Recent Activity
Jun 2, 2026
other
iBio to Participate in Upcoming Healthcare Investor Conferences
<p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (<strong>NASDAQ: IBIO</
May 18, 2026
Insider
Stoner Elizabeth was granted 60,000 shares
Director
May 15, 2026
SEC
Elizabeth Stoner filed a Form 3 initial statement of beneficial ownership with iBio, Inc. (IBIO), reporting no securitie
3 — Impact 2/10
May 12, 2026
SEC
iBio reported Q3 FY2026 results with EPS of -$0.07 (GAAP) vs consensus -$0.06, a miss of ~16.7%. Revenue was $0, in line
PRESS-RELEASE — Impact 6/10
May 8, 2026
SEC
iBio appointed Dr. Elizabeth Stoner to its Board of Directors, replacing Evert Schimmelpennink who resigned. Dr. Stoner
8-K — Impact 2/10
Mar 26, 2026
Insider
Banjak Marc bought 12,500 shares
Chief Legal Officer @ $1.64 ($20.5K)
Mar 19, 2026
Insider
Brenner Martin bought 12,336 shares
See Remarks @ $2.02 ($24.9K)
Inst.
MARSHALL WACE, LLP — DOUBLED
620,602 shares ($1.2M)
Price Targets
$5.53
+226.9% upside
Strong Buy
Current $1.69
Low $4.20
Median $5.50
High $7.00
8 analysts
$4.20
$7.00
Analyst Ratings
4Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | Raymond James | INITIATE | Outperform |
| Apr 9, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 18, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 3, 2026 | Jones Trading | INITIATE | Buy |
| Feb 12, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.06 ▼ -0.7% | $-0.09 — $-0.03 | 80% YoY | 8 |
| Next Q | $-0.08 ▲ +3.1% | $-0.09 — $-0.07 | 30% YoY | 4 |
| Current FY | $-0.33 ▲ +0.5% | $-0.47 — $-0.25 | 81% YoY | 8 |
| Next FY | $-0.31 ▲ +1.9% | $-0.44 — $-0.22 | 6% YoY | 7 |
Latest Reports
NEUTRAL
3
2/10
Elizabeth Stoner filed a Form 3 initial statement of beneficial ownership with iBio, Inc. (IBIO), reporting no securitie
May 15, 2026
BEARISH
PRESS-RELEASE
6/10
iBio reported Q3 FY2026 results with EPS of -$0.07 (GAAP) vs consensus -$0.06, a miss of ~16.7%. Revenue was $0, in line
May 12, 2026
MIXED
Press
6/10
iBio, Inc. announced plans to expand its pipeline into pulmonary hypertension associated with heart failure with preserv
Mar 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $2.1M | — |
| BALYASNY ASSET MANAGEMENT L.P. | $1.9M | DOUBLED |
| CITADEL ADVISORS LLC | $1.8M | — |
| MARSHALL WACE, LLP | $1.2M | DOUBLED |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $784.2K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Stoner Elizabeth | A | $0.00 |
| Mar 26, 2026 | Banjak Marc | BUY | $20.5K |
| Mar 19, 2026 | Brenner Martin | BUY | $24.9K |
| Mar 19, 2026 | Duran Felipe | BUY | $50.1K |
| Jan 28, 2026 | Duran Felipe | A | $0.00 |
17 institutional holders with $10.5M total value (5,519,764 shares) as of 2026-Q1. Top holders: VANGUARD, BALYASNY, CITADEL. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1,088,299 | $2.1M | 19.7% | — |
| 2 | BALYASNY ASSET MANAGEMENT L.P. | 1,010,955 | $1.9M | 18.3% | DOUBLED +10440.2% |
| 3 | CITADEL ADVISORS LLC | 956,429 | $1.8M | 17.3% | — |
| 4 | MARSHALL WACE, LLP | 620,602 | $1.2M | 11.2% | DOUBLED +411.7% |
| 5 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 412,725 | $784.2K | 7.5% | — |
| 6 | TWO SIGMA INVESTMENTS, LP | 408,858 | $776.8K | 7.4% | — |
| 7 | BANK OF AMERICA CORP /DE/ | 290,413 | $551.8K | 5.3% | DOUBLED +150.8% |
| 8 | VANGUARD FIDUCIARY TRUST CO | 205,015 | $389.5K | 3.7% | — |
| 9 | GOLDMAN SACHS GROUP INC | 200,212 | $380.4K | 3.6% | — |
| 10 | STATE STREET CORP | 141,199 | $268.3K | 2.6% | ADD +93.7% |
| 11 | BlackRock, Inc. | 131,215 | $249.3K | 2.4% | DOUBLED +207.1% |
| 12 | MORGAN STANLEY | 30,937 | $58.8K | 0.6% | DOUBLED +48312.3% |
| 13 | Vanguard Personalized Indexing Management, LLC | 12,180 | $23.1K | 0.2% | — |
| 14 | Vanguard Global Advisers, LLC | 5,460 | $10.4K | 0.1% | — |
| 15 | ROYAL BANK OF CANADA | 3,891 | $7.0K | 0.1% | DOUBLED +12400.0% |
| 16 | CITIGROUP INC | 1,373 | $2.6K | 0.0% | NEAR_EXIT -80.5% |
| 17 | WELLS FARGO & COMPANY/MN | 1 | $2.00 | 0.0% | NEAR_EXIT -75.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | 121,286 | 620,602 | +411.7% | $1.2M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 115,793 | 290,413 | +150.8% | $551.8K | 2026-Q1 |
| STATE STREET CORP | ADD | 72,899 | 141,199 | +93.7% | $268.3K | 2026-Q1 |
| BlackRock, Inc. | DOUBLED | 42,727 | 131,215 | +207.1% | $249.3K | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 10,400 | 1,096,179 | +10440.2% | $2.1M | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 274,070 | 883,149 | +222.2% | $1.7M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 145 | 115,793 | +79757.2% | $223.5K | 2025-Q4 |
| STATE STREET CORP | DOUBLED | 33,699 | 72,899 | +116.3% | $140.7K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 57 | 27,595 | +48312.3% | $53.3K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 4 | 1 | -75.0% | $2.00 | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 143,861 | 274,070 | +90.5% | $226.9K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1 | 4 | +300.0% | $3.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 28,603 | 1 | -100.0% | $1.00 | 2025-Q3 |
| BlackRock, Inc. | DOUBLED | 5,574 | 42,727 | +666.5% | $171.8K | 2025-Q1 |
| UBS Group AG | DOUBLED | 899 | 25,890 | +2779.9% | $104.1K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 48 | 3,775 | +7764.6% | $15.2K | 2025-Q1 |
| ROYAL BANK OF CANADA | DOUBLED | 8 | 1,000 | +12400.0% | $4.0K | 2025-Q1 |
| VANGUARD GROUP INC | DOUBLED | 35,998 | 73,145 | +103.2% | $179.2K | 2024-Q4 |
| UBS Group AG | DOUBLED | 1 | 899 | +89800.0% | $2.2K | 2024-Q4 |
| FMR LLC | TRIM | 3 | 1 | -66.7% | $2.00 | 2024-Q4 |
| ROYAL BANK OF CANADA | NEAR_EXIT | 37 | 8 | -78.4% | — | 2024-Q3 |
| CITIGROUP INC | NEAR_EXIT | 215 | 42 | -80.5% | $93.00 | 2024-Q3 |
4 unique insiders with 7 transactions. Net insider value: $95.6K ($95.6K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Stoner Elizabeth | Director | AWARD | 60,000 | — | — |
| Mar 26, 2026 | Banjak Marc | Chief Legal Officer | BUY | 12,500 | $1.64 | $20.5K |
| Mar 19, 2026 | Brenner Martin | See Remarks | BUY | 12,336 | $2.02 | $24.9K |
| Mar 19, 2026 | Duran Felipe | Chief Financial Officer | BUY | 24,835 | $2.02 | $50.1K |
| Jan 28, 2026 | Duran Felipe | Chief Financial Officer | AWARD | 179,000 | — | — |
| Jan 28, 2026 | Banjak Marc | Chief Legal Officer | AWARD | 146,000 | — | — |
| Jan 28, 2026 | Brenner Martin | See Remarks | AWARD | 479,000 | — | — |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 1 mixed, 4 neutral. Avg impact: 4.3/10.
NEUTRAL
3
2/10
Elizabeth Stoner filed a Form 3 initial statement of beneficial ownership with iBio, Inc. (IBIO), re
May 15, 2026
BEARISH
PRESS-RELEASE
6/10
iBio reported Q3 FY2026 results with EPS of -$0.07 (GAAP) vs consensus -$0.06, a miss of ~16.7%. Rev
May 12, 2026
NEUTRAL
8-K
2/10
iBio appointed Dr. Elizabeth Stoner to its Board of Directors, replacing Evert Schimmelpennink who r
May 8, 2026
MIXED
8-K
6/10
iBio announced regulatory clearance to initiate a Phase 1 clinical trial of its drug candidate IBIO-
Apr 8, 2026
NEUTRAL
CLUSTER
3/10
iBio's Chief Legal Officer, Marc Banjak, purchased 12,500 shares in the open market for approximatel
Mar 27, 2026
BULLISH
CLUSTER
5/10
Two insiders at iBio, Inc. (IBIO) purchased shares in the open market on March 19, 2026, including C
Mar 23, 2026
NEUTRAL
EFFECT
3/10
iBio, Inc. has received SEC effectiveness for its shelf registration statement on Form S-3, allowing
Mar 9, 2026
BEARISH
S-3
7/10
iBio, Inc. (IBIO) has filed an S-3 shelf registration statement with the SEC, authorizing the potent
Feb 27, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 4 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.53 mean target
+226.9% upside
Strong Buy (1.13)
$4.20 Low
$7.00 High
| Metric | Value |
|---|---|
| Current Price | $1.69 |
| Target Low | $4.20 |
| Target Mean | $5.53 |
| Target Median | $5.50 |
| Target High | $7.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.13) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.06 | $-0.09 | $-0.03 | 80.1% | -0.7% | 1↑ 0↓ | $0.0B | -71.4% | 8 |
| Next Q 2026-09-30 |
$-0.08 | $-0.09 | $-0.07 | 29.5% | +3.1% | — | $0.0B | -100.0% | 4 |
| Current FY 2026-06-30 |
$-0.33 | $-0.47 | $-0.25 | 81.1% | +0.5% | 2↑ 0↓ | $0.0B | -60.7% | 8 |
| Next FY 2027-06-30 |
$-0.31 | $-0.44 | $-0.22 | 6.1% | +1.9% | 0↑ 2↓ | $0.0B | -45.5% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.064 | |
| 7d ago | $-0.063 | -0.001 |
| 30d ago | $-0.063 | -0.000 |
| 60d ago | $-0.062 | -0.002 |
| 90d ago | $-0.062 | -0.002 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | Raymond James | INITIATE | — | Outperform |
| Apr 9, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | Jones Trading | INITIATE | — | Buy |
| Feb 12, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
other
iBio to Participate in Upcoming Healthcare Investor Conferences
<p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (<strong>NASDAQ: IBIO</strong>) (“iBio” or the “Company”), an AI-driven i
Jun 2, 2026
other
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
<p align="center"><em>IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve bo
May 12, 2026
earnings
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
<p align="center"><em>Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia</em></p>
May 8, 2026
other
iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
<p align="justify">SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=_AMCoifdo5UhyoXyg0h9YqZgSdyYC8b3L
Apr 30, 2026
earnings_calendar
IBIO Q3 2026 Earnings Scheduled — 2026-04-30
Mar 16, 2026
fda
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET <pre>Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET
Mar 9, 2026
fda
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet <pre>Study demo